The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Aug 18, 2026
Snapshot (as of Aug 18, 2026): Bristol-Myers Squibb Company (BMY) pays a $2.51 annual dividend ($0.63 quarterly), yielding 3.88% at $64.63/share. Next ex-dividend date 2026-07-02. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 3.88%
Annual Dividend: $2.51 per share
Payout Ratio: 54.9%
Ex-Dividend Date: 2026-07-02
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 55
Bristol-Myers Squibb Company dividend investors are looking at a global biopharmaceutical business built around franchises like Eliquis, Opdivo, and Revlimid, spanning oncology, cardiovascular health, and immunology. The current yield stands at 3.88%, with a trailing annual dividend rate of $2.51 per share paid quarterly. The next ex-dividend date is July 2, 2026. A beta of 0.225 points to low price volatility, which suits income-focused investors who prioritize a steady payout over share price swings.
Bristol-Myers Squibb Company pays out 54.9% of earnings as dividends, a payout ratio classified as moderate (40-60%). That level leaves meaningful earnings coverage above the dividend, supported by a broad portfolio of commercial-stage therapies across multiple therapeutic areas including hematology, oncology, and cardiovascular disease. Bristol-Myers Squibb Company dividend safety faces its most visible pressure from patent exposure on key products, a risk inherent to drug manufacturers where revenue concentration around blockbuster therapies can shift quickly.
Bristol-Myers Squibb Company dividend history shows a CAGR of 4.3% per year from 2006 to 2025. Per-share payments grew from $1.12 to $2.48 over that period (2026 is a partial year and excluded from the rate calculation). The largest annual increase in the window was 39.6% in 2020, though the history also contains at least one year-over-year decline exceeding 5%, so growth has not been linear.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +4.7% | $2.16 (2022) | $2.48 (2025) |
| 5-Year | +1.6% | $2.29 (2020) | $2.48 (2025) |
| 10-Year | +5.2% | $1.49 (2015) | $2.48 (2025) |
BMY fits income-focused investors who want a moderate yield from a large, diversified biopharmaceutical business. At 3.88%, the current yield sits above the 5-year average of 3.33%, meaning buyers today are locking in a higher-than-average income rate relative to BMY's own history. The moderate (2-4%) yield classification and 54.9% payout ratio together describe a dividend that is neither stretched nor particularly aggressive. The trade-off is growth: 4.3% annualized over nearly two decades is real but slow, and the history includes declines. Bristol-Myers Squibb Company stock offers income with low price volatility (beta 0.225), but investors accept limited dividend acceleration in return.
| Payment Date | Amount per Share |
|---|---|
| 2026-07-02 | $0.6300 |
| 2026-04-02 | $0.6300 |
| 2026-01-02 | $0.6300 |
| 2025-10-03 | $0.6200 |
| 2025-07-03 | $0.6200 |
| 2025-04-04 | $0.6200 |
| 2025-01-03 | $0.6200 |
| 2024-10-04 | $0.6000 |
| 2024-07-05 | $0.6000 |
| 2024-04-04 | $0.6000 |
| Year | Total Dividends |
|---|---|
| 2026 | $1.8900 |
| 2025 | $2.4800 |
| 2024 | $2.4000 |
| 2023 | $2.2800 |
| 2022 | $2.1600 |
Project income from BMY with the BMY dividend calculator or track your full portfolio with the dividend tracker.